CN112641091A - 一种含叶酸的复合抗氧化剂 - Google Patents
一种含叶酸的复合抗氧化剂 Download PDFInfo
- Publication number
- CN112641091A CN112641091A CN202011345650.1A CN202011345650A CN112641091A CN 112641091 A CN112641091 A CN 112641091A CN 202011345650 A CN202011345650 A CN 202011345650A CN 112641091 A CN112641091 A CN 112641091A
- Authority
- CN
- China
- Prior art keywords
- parts
- folic acid
- antioxidant
- acid
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 62
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 60
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims abstract description 42
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 235000019152 folic acid Nutrition 0.000 title claims abstract description 21
- 239000011724 folic acid Substances 0.000 title claims abstract description 21
- 229960000304 folic acid Drugs 0.000 title claims abstract description 21
- 239000002131 composite material Substances 0.000 title claims abstract description 8
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 59
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 48
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims abstract description 40
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 24
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 24
- 239000011718 vitamin C Substances 0.000 claims abstract description 24
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims abstract description 21
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 21
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 21
- 235000010265 sodium sulphite Nutrition 0.000 claims abstract description 20
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 19
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 19
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 19
- 239000011648 beta-carotene Substances 0.000 claims abstract description 19
- 229960002747 betacarotene Drugs 0.000 claims abstract description 19
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 19
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims abstract description 11
- 150000002224 folic acids Chemical class 0.000 claims abstract description 11
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims description 26
- 239000000126 substance Chemical class 0.000 claims description 11
- 229940065207 methylfolic acid Drugs 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 2
- 230000000181 anti-adherent effect Effects 0.000 claims description 2
- 239000003911 antiadherent Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000008191 folinic acid Nutrition 0.000 claims description 2
- 239000011672 folinic acid Substances 0.000 claims description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229960001691 leucovorin Drugs 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 230000032683 aging Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000037149 energy metabolism Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 5
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 5
- 235000005487 catechin Nutrition 0.000 description 5
- 229950001002 cianidanol Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229930003427 Vitamin E Natural products 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 235000017471 coenzyme Q10 Nutrition 0.000 description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000008558 metabolic pathway by substance Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- -1 oxygen radicals Chemical class 0.000 description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- NRGONRDRXCPMIC-GDKBPFBDSA-N N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CC(C=O)C(O)=O)C(O)=O)C=C1 Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CC(C=O)C(O)=O)C(O)=O)C=C1 NRGONRDRXCPMIC-GDKBPFBDSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- YQCIWBXEVYWRCW-UHFFFAOYSA-N methane;sulfane Chemical compound C.S YQCIWBXEVYWRCW-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及抗氧化剂技术领域,具体涉及一种含叶酸的复合抗氧化剂,所述含叶酸的复合抗氧化剂包括如下组分:硫辛酸、叶酸类化合物、维生素C、亚硫酸钠和/或亚硫酸氢钠、β‑胡萝卜素和乙二胺己乙酸,本发明具有抗氧化效果显著的优点。
Description
技术领域
本发明涉及抗氧化剂技术领域,具体涉及一种含叶酸的复合抗氧化剂。
背景技术
人们在正常生活中,生命的维持需要体内复杂的生化反应,产生能量代谢及物质代谢,来维持人体各器官功能的正常运行,其中有多种物质在复杂的机体生化反应中起了重要的作用,如果没有这些物质,机体就不能生存,这些物质被认为是人体重要的营养物质,包括多种维生素和其他生化物质等。
在人体内的能量及物质代谢当中,三羧酸循环是能量代谢的枢纽,在全身细胞的线粒体当中进行,通过三羧酸循环,产生较多的能量,维持人体的各种生理、生化的正常进行,以维持人体的正常机能运行。但在产生能量的过程中,同时会产生多种氧化物质,这种氧化物质多数为代谢中产生的电子,在组织中形成氧化自由基,造成组织细胞的氧化损伤,造成人体细胞组织的变性及老化。这就需要抗氧化剂来对抗这种氧化自由基,随时来保护人体在能量代谢中产生的氧化自由基所带来的全身组织损伤,使机体免于氧化损伤所带来的过早老化及衰老,从而延长人体的寿命。
体内的自由基主要分为半醌类自由基、氧自由基及各种氨基酸、核苷酸的碱基以及其他生物分子所产生的碳硫中心自由基三大类。过量自由基是引起细胞破坏及机体损伤的一个重要损伤因子。自由基的毒性反应与炎症、免疫性疾病、辐射损伤、衰老及肿瘤的发生密切相关。竞争自由基的物质就是抗氧化剂。目前常用的抗氧化剂主要有维生素C和维生素E,维生素C主要以清除·OH为主,但需大剂量使用才能达到目的,但同时,大剂量维生素C使用容易导致酸中毒。维生素E主要通过抑制细胞膜上的脂质过氧化来达到抗氧化的目的,但长期使用则有潜在的致突变风险。
现有市面上的抗氧化自由基中,大部分都是单独的抗氧化成分,这些成分在对抗氧化自由基当中虽然起了一定的作用,有利于维护机体的健康状态;但是因为市面上这种抗氧化剂其所含的成分较为单一,抗氧化作用有限,不能更好地满足全身细胞组织抗氧化的需要,不能弥补全身各组织细胞所产生的氧化自由基所带来的损害,故不能更好的消除人体能量代谢中所产生的健康隐患。
中国专利申请CN1481784A公开了一种缓释型微胶囊化复方抗氧化剂,该胶囊的囊心由儿茶素50%-70%,维生素C 30%-10%、β-胡萝卜素5.0%-15%、辅酶Q10%-5.0%、亚硫酸钠或亚硫酸氢钠0.1%-1.0%、乙二胺己乙酸0.1%-1.0%组成,并以生物缓释型成膜材料乙基纤维素和壳聚糖为壁材,制备缓释型微胶囊。它对各类自由基均有较好的清除作用,且脂溶性较儿茶素显著增强、稳定性好、体外抗氧化活性和体内抗氧化活性较儿茶素均有明显提高,并能使其以缓释形式释放,提高了儿茶素的生物利用度。此抗氧化剂可用于抗衰老、自由基相关疾病患者的保健食品、食品保鲜、油脂抗氧化以及牙膏、美容养颜、防晒油等日用化工产品。但是该胶囊以儿茶素为主,生产成本较高,且抗氧化性能有待进一步提高。
中国专利申请CN111035012A公开了一种抗氧化营养组合胶囊及其制备方法,其组合了β-烟酰胺单核苷酸、辅酶Q10、维生素E、维生素C、硫辛酸等多种抗氧化剂,β-烟酰胺单核苷酸具有调节代谢延长寿命的功效,互相增强抗氧化及抗衰老效果,是全身组织细胞保持健康年轻态,使生命更长久;同时针对于中国饮食特点的缺陷设计而成,防止因某些营养物质的缺乏导致的能量及物质代谢障碍,组合了维生素B6、维生素B12及叶酸组合,三者相互配合可以促进蛋氨酸代谢,实现人体能量代谢及物质代谢的枢纽,有效预防动脉硬化,增加了辅酶Q10具有抗氧化、抗衰老等功效,可以起到保护心脏及身体重要器官的作用,可以维持人体机能的健康状态。但是该胶囊的抗氧化性能有待进一步提高。
随着人们生活水平和健康意识的不断提高,人们对抗氧化的要求也越来越高,高效且具有多功能的抗氧化剂越来越受到人们的青睐。人们一方面希望可以通过抑制氧化酶,减少自由基的生成,以提高其抗氧化作用;另一方面也希望通过灭活自由基,保护抗氧化酶,提高体内抗氧化酶的活性进而增强抗氧化作用。人们对具有较好的清除体内自由基能力的复合抗氧化剂的需求也越来越高。
因此,利用开发一种能解决上述技术问题的含叶酸的复合抗氧化剂是非常必要的。
发明内容
本发明的目的是克服现有技术的不足而提供一种抗氧化效果显著的含叶酸的复合抗氧化剂。
本发明是通过以下技术方案予以实现的:
一种含叶酸的复合抗氧化剂,包括如下组分:硫辛酸、叶酸类化合物、维生素C、亚硫酸钠和/或亚硫酸氢钠、β-胡萝卜素和乙二胺己乙酸。
优选地,按照重量份计,所述复合抗氧化剂包括如下组分:硫辛酸40-70份、叶酸类化合物8-30份、维生素C 5-25份、亚硫酸钠和/或亚硫酸氢钠0.1-1份、β-胡萝卜素5-15份和乙二胺己乙酸0.1-1份。
优选地,按照重量份计,所述复合抗氧化剂包括如下组分:硫辛酸55份、叶酸类化合物20份、维生素C15份、亚硫酸钠和/或亚硫酸氢钠0.5份、β-胡萝卜素10份和乙二胺己乙酸0.5份。
优选地,所述叶酸类化合物为叶酸、甲酰四氢叶酸、L-甲基叶酸、叶酸可药用盐、叶酸或叶酸可药用盐的活性代谢产物和可在体内代谢和/或生成叶酸的物质中的一种或几种。
本发明还涉及一种制剂,包括上述的复合抗氧化剂。
优选地,所述制剂还包括至少一种药学上可接受的赋形剂。
更优选地,所述赋形剂为稀释剂、粘合剂、崩解剂、润滑剂、着色剂、增味剂、pH调节剂、缓冲剂、均质剂、防腐剂、抗粘合剂、助流剂、酸化剂和甜味剂中的一种或几种。
优选地,所述制剂为片剂、颗粒剂或胶囊剂。
本发明还涉及上述制剂的制备工艺,将所述复合抗氧化剂与赋形剂一起成粒以形成药物颗粒,制成各种剂型。
本发明还涉及上述的复合抗氧化剂或上述的制剂或上述的制备工艺制备得到的制剂在制备用于营养食疗的食品、功能食品、医疗辅助食品、保健食品、化妆品和药品中的应用。
本发明的有益效果是:
(1)本发明的复合抗氧化剂中硫辛酸与维生素C、β-胡萝卜素和亚硫酸钠/亚硫酸氢钠结合,扩大了消除自由基的种类,显著提高了抗衰老功效。
(2)叶酸和亚硫酸钠/亚硫酸氢钠,减弱了硫辛酸的光敏感性,增强了硫辛酸的稳定性,同时叶酸能够增强硫辛酸抗衰老的生物功效,有利于本发明的复合抗氧化剂稳定发挥抗衰老功效。
(3)本发明的复合抗氧化剂中各个组分发生了协同作用,同时实现了抑制氧化酶和灭活自由基的作用,抗衰老效果显著。
具体实施方式
下面结合具体实施例来进一步描述本发明,本发明的优点和特点将会随着描述而更为清楚。但这些实施例仅是范例性的,并不对本发明的范围构成任何限制。本领域技术人员应该理解的是,在不偏离本发明的精神和范围下可以对本发明技术方案的细节和形式进行修改或替换,但这些修改和替换均落入本发明的保护范围内。
实施例1
一种复合抗氧化剂,包括如下组分:硫辛酸40份、叶酸8份、维生素C 5份、亚硫酸钠0.1份、β-胡萝卜素5份和乙二胺己乙酸0.1份。
实施例2
一种复合抗氧化剂,包括如下组分:硫辛酸70份、甲酰四氢叶酸30份、维生素C 25份、亚硫酸氢钠1份、β-胡萝卜素15份和乙二胺己乙酸1份。
实施例3
一种复合抗氧化剂,包括如下组分:硫辛酸55份、L-甲基叶酸20份、维生素C15份、亚硫酸钠0.5份、β-胡萝卜素10份和乙二胺己乙酸0.5份。
对比例1
与实施例3的区别仅在于复合抗氧化剂的组成不同,将15份维生素C替换为15份维生素E,其余条件均相同。
对比例2
与实施例3的区别仅在于复合抗氧化剂中各组分的用量配比不同,其余条件均相同,具体如下:
一种复合抗氧化剂,包括如下组分:硫辛酸30份、L-甲基叶酸10份、维生素C 35份、亚硫酸钠2.5份、β-胡萝卜素20份和乙二胺己乙酸3.5份。
对比例3
与实施例3的区别仅在于复合抗氧化剂中L-甲基叶酸替换为等质量的亚硫酸钠,其余条件均相同,具体如下:
一种复合抗氧化剂,包括如下组分:硫辛酸55份、维生素C15份、亚硫酸钠20.5份、β-胡萝卜素10份和乙二胺己乙酸0.5份。
对比例4
与实施例3的区别仅在于复合抗氧化剂中亚硫酸钠替换为等质量的L-甲基叶酸,其余条件均相同,具体如下:
一种复合抗氧化剂,包括如下组分:硫辛酸55份、L-甲基叶酸20.5份、维生素C15份、β-胡萝卜素10份和乙二胺己乙酸0.5份。
对比例5
与实施例3的区别仅在于复合抗氧化剂中不添加L-甲基叶酸和亚硫酸钠,其余条件均相同,具体如下:
一种复合抗氧化剂,包括如下组分:硫辛酸55份、维生素C15份、β-胡萝卜素10份和乙二胺己乙酸0.5份。
对比例6
与实施例3的区别仅在于复合抗氧化剂中维生素C15份替换为亚硫酸钠7.5份、β-胡萝卜素7.5份,其余条件均相同,具体如下:
一种复合抗氧化剂,包括如下组分:硫辛酸55份、L-甲基叶酸20份、亚硫酸钠8份、β-胡萝卜素17.5份和乙二胺己乙酸0.5份。
对比例7
与实施例3的区别仅在于复合抗氧化剂中亚硫酸钠0.5份、β-胡萝卜素10份替换为维生素C10.5份,其余条件均相同,具体如下:
一种复合抗氧化剂,包括如下组分:硫辛酸55份、L-甲基叶酸20份、维生素C 25.5份和乙二胺己乙酸0.5份。
测试例1
为了进一步证明本发明的优点,本发明对上述实施例及对比例的复合抗氧化剂进行抗氧化功能验证。抗氧化功能验证试验参照《保健食品检验与评价技术规范》(2003版)中抗氧化功能检验方法与操作规程进行。
(1)动物实验
采用10月龄雌性清洁级ICR小鼠(40±5g),随机分为一个空白对照组及10个受试样品组(实施例1-3为实验组,对比例1-7为对照组),每组10只。10个受试样品组的剂量为1.35g/kg,一天1次,连续灌胃30天,实验结束时处死动物,测丙二醛(MDA)含量、超氧化物歧化酶(SOD)活力及谷胱氨肽过氧化物酶(GSH-Px)活力。
(2)效果验证
数据采用均数±标准差表示,进行单因素方差分析,以P<0.05表示存在显著性差异。结果如表1所示。
表1
注:与对照组相比,*P<0.05。
上述详细说明是针对本发明其中之一可行实施例的具体说明,该实施例并非用以限制本发明的专利范围,凡未脱离本发明所为的等效实施或变更,均应包含于本发明技术方案的范围内。
Claims (10)
1.一种含叶酸的复合抗氧化剂,其特征在于,包括如下组分:硫辛酸、叶酸类化合物、维生素C、亚硫酸钠和/或亚硫酸氢钠、β-胡萝卜素和乙二胺己乙酸。
2.根据权利要求1所述的复合抗氧化剂,其特征在于,按照重量份计,包括如下组分:硫辛酸40-70份、叶酸类化合物8-30份、维生素C 5-25份、亚硫酸钠和/或亚硫酸氢钠0.1-1份、β-胡萝卜素5-15份和乙二胺己乙酸0.1-1份。
3.根据权利要求1所述的复合抗氧化剂,其特征在于,按照重量份计,包括如下组分:硫辛酸55份、叶酸类化合物20份、维生素C15份、亚硫酸钠和/或亚硫酸氢钠0.5份、β-胡萝卜素10份和乙二胺己乙酸0.5份。
4.根据权利要求1所述的复合抗氧化剂,其特征在于,所述叶酸类化合物为叶酸、甲酰四氢叶酸、L-甲基叶酸、叶酸可药用盐、叶酸或叶酸可药用盐的活性代谢产物和可在体内代谢和/或生成叶酸的物质中的一种或几种。
5.一种制剂,其特征在于,包括权利要求1-4任一所述的复合抗氧化剂。
6.根据权利要求5所述的制剂,其特征在于,所述制剂还包括至少一种药学上可接受的赋形剂。
7.根据权利要求6所述的制剂,其特征在于,所述赋形剂为稀释剂、粘合剂、崩解剂、润滑剂、着色剂、增味剂、pH调节剂、缓冲剂、均质剂、防腐剂、抗粘合剂、助流剂、酸化剂和甜味剂中的一种或几种。
8.根据权利要求5所述的制剂,其特征在于,所述制剂为片剂、颗粒剂或胶囊剂。
9.权利要求6-8任一所述的制剂的制备工艺,其特征在于,将所述复合抗氧化剂与赋形剂一起成粒以形成药物颗粒,制成各种剂型。
10.权利要求1-4任一所述的复合抗氧化剂或权利要求5-8任一所述的制剂或权利要求9所述的制备工艺制备得到的制剂在制备用于营养食疗的食品、功能食品、医疗辅助食品、保健食品、化妆品和药品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011345650.1A CN112641091A (zh) | 2020-11-25 | 2020-11-25 | 一种含叶酸的复合抗氧化剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011345650.1A CN112641091A (zh) | 2020-11-25 | 2020-11-25 | 一种含叶酸的复合抗氧化剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112641091A true CN112641091A (zh) | 2021-04-13 |
Family
ID=75349471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011345650.1A Pending CN112641091A (zh) | 2020-11-25 | 2020-11-25 | 一种含叶酸的复合抗氧化剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112641091A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1481784A (zh) * | 2003-07-07 | 2004-03-17 | 长沙国藩科技有限公司 | 一种缓释型微胶囊化复方抗氧化剂 |
CN1524447A (zh) * | 2003-09-16 | 2004-09-01 | 曾繁玉 | 抗氧化剂组合物 |
US20050119218A1 (en) * | 2001-08-29 | 2005-06-02 | C/O Premier Micronutrient Corporation | Multiple antioxidant micronutrients |
JP2015218140A (ja) * | 2014-05-19 | 2015-12-07 | 医療法人千清會 鈴木脳神経外科 | 抗酸化サプリメント |
CN107997155A (zh) * | 2017-12-01 | 2018-05-08 | 北京斯利安药业有限公司 | 一种组合物、其应用和抗氧化、改善记忆力的产品 |
CN108157639A (zh) * | 2018-01-30 | 2018-06-15 | 上海依蕴宠物用品有限公司 | 一种富含天然硫辛酸的强抗氧化宠物食品及制备方法 |
CN109701027A (zh) * | 2019-01-24 | 2019-05-03 | 北京斯利安药业有限公司 | 一种新型的增强叶酸抗氧性的叶酸药物组合物及叶酸药物制剂 |
CN110664644A (zh) * | 2019-09-25 | 2020-01-10 | 北京斯利安药业有限公司 | 一种含叶酸的护肤组合物、精华及其制备方法 |
CN111035012A (zh) * | 2019-12-16 | 2020-04-21 | 青岛赛珥生物医学科技有限公司 | 一种抗氧化营养组合胶囊及其制备方法 |
-
2020
- 2020-11-25 CN CN202011345650.1A patent/CN112641091A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050119218A1 (en) * | 2001-08-29 | 2005-06-02 | C/O Premier Micronutrient Corporation | Multiple antioxidant micronutrients |
CN1481784A (zh) * | 2003-07-07 | 2004-03-17 | 长沙国藩科技有限公司 | 一种缓释型微胶囊化复方抗氧化剂 |
CN1524447A (zh) * | 2003-09-16 | 2004-09-01 | 曾繁玉 | 抗氧化剂组合物 |
JP2015218140A (ja) * | 2014-05-19 | 2015-12-07 | 医療法人千清會 鈴木脳神経外科 | 抗酸化サプリメント |
CN107997155A (zh) * | 2017-12-01 | 2018-05-08 | 北京斯利安药业有限公司 | 一种组合物、其应用和抗氧化、改善记忆力的产品 |
CN108157639A (zh) * | 2018-01-30 | 2018-06-15 | 上海依蕴宠物用品有限公司 | 一种富含天然硫辛酸的强抗氧化宠物食品及制备方法 |
CN109701027A (zh) * | 2019-01-24 | 2019-05-03 | 北京斯利安药业有限公司 | 一种新型的增强叶酸抗氧性的叶酸药物组合物及叶酸药物制剂 |
CN110664644A (zh) * | 2019-09-25 | 2020-01-10 | 北京斯利安药业有限公司 | 一种含叶酸的护肤组合物、精华及其制备方法 |
CN111035012A (zh) * | 2019-12-16 | 2020-04-21 | 青岛赛珥生物医学科技有限公司 | 一种抗氧化营养组合胶囊及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5352235B2 (ja) | 酸化型補酵素q10含有高吸収性経口用組成物 | |
US7220429B2 (en) | Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing | |
US9849096B2 (en) | Neuroprotective effect of carotenoids in brain | |
EP2704734B1 (en) | Composition useful for the treatment of lipid metabolism disorders | |
US8124139B2 (en) | Compound preparation for quickly reducing oxidative stress and preparation of the same | |
AU2005204044B2 (en) | Antiaging composition | |
CA3037968A1 (en) | Alpha-ketobutyrate, 2-hydroxybutyrate, and alpha-ketoglutarate for stimulating hair growth | |
US20050154066A1 (en) | Antiaging composition | |
JPWO2007013556A1 (ja) | 癌予防用組成物 | |
JP2010030901A (ja) | ストレス症状の緩和または予防剤 | |
CN112156143B (zh) | 一种具有抗氧化功能的复合营养素组合物 | |
CN101288675A (zh) | 一种治疗心脑血管类疾病的药物及其生产方法 | |
CN112641091A (zh) | 一种含叶酸的复合抗氧化剂 | |
JP2003335668A (ja) | 経口用美肌用剤 | |
JPH07330593A (ja) | 疲労改善剤 | |
JP5341422B2 (ja) | 蜂の子およびローヤルゼリーを含有する抗酸化組成物 | |
JP7407515B2 (ja) | 内服用組成物 | |
US20080089905A1 (en) | COMPOUNDS FOR STIMULATING STEM CELL PROLIFERATION INCLUDING AFA-OMEGA (EtOH) | |
WO2015002279A1 (ja) | グルタチオン生成促進用組成物 | |
CN109588727B (zh) | 一种辅助预防心血管疾病的保健食品 | |
US20240148026A1 (en) | Liquid-phase, supplementary feed composition containing coenzyme q10 | |
JPWO2008093764A1 (ja) | 糖尿病予防または治療用組成物 | |
AU2023201650A1 (en) | Formulation to aid metabolism and sleep | |
JPWO2007034852A1 (ja) | 延命用組成物及び寿命を延長する方法 | |
CN114917244A (zh) | 一种复合型维生素软胶囊及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |